- Home
- SITC vs MGNX Comparison
SITC vs MGNX Comparison
Compare SITC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | MGNX |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | United States |
| Employees | 155 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.9M | 220.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SITC | MGNX |
|---|---|---|
| Price | $4.32 | $4.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.00 | $5.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 123.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $1.30 |
| 52 Week High | $12.39 | $5.08 |
Technical Indicators
Market Signals| Indicator | SITC | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 46.57 |
| Support Level | $3.91 | $1.49 |
| Resistance Level | $5.63 | $4.55 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 45.51 | 12.57 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.